Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

INTRODUCTION: The combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). However, the response of the tumor microenvironment to FOLFOX-Bev is still largely unexplored. METHODS: We conducted single-cell transcriptomic analysis of CRC samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Meiling, Yang, Ciqiu, Ma, Dong, Li, Zijun, Zhao, Wei, Yang, Dongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421721/
https://www.ncbi.nlm.nih.gov/pubmed/37576892
http://dx.doi.org/10.3389/fonc.2023.1219642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421721/
https://www.ncbi.nlm.nih.gov/pubmed/37576892
http://dx.doi.org/10.3389/fonc.2023.1219642

Ejemplares similares